Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Status:
Completed
Trial end date:
2017-03-15
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if the addition of dutasteride to a
regimen with abiraterone acetate and prednisone will improve on therapy in patients with
castrate-resistant prostate cancer and metastatic disease. This study will also help
determine the side effects of the study treatment and how often they occur.